<DOC>
	<DOCNO>NCT02419118</DOCNO>
	<brief_summary>Daratumumab new treatment patient myeloma . While many patient benefit treatment mechanism ( ) failure poorly understood . This study aim clarify aspect resistance treatment daratumumab order improve patient outcomes future .</brief_summary>
	<brief_title>`` Monoclonal Antibodies Treatment Multiple Myeloma . Emphasis CD38 Antibody Daratumumab ``</brief_title>
	<detailed_description>The effector mechanisms daratumumab extensively studied vitro , vivo correlate key determinant success failure daratumumab use alone combination lenalidomide treatment patient myeloma clarify . There potentially wide spectrum factor may influence quality duration response follow treatment daratumumab . The integrity patient 's immune system may important . Prior line chemotherapy myeloma disease may impair humural ( i.e . complement ) cellular ( i.e . ADCC ) effector mechanisms importance response daratumumab . Also intrinsic property tumor cell interaction myeloma cell bone marrow microenvironment could make myeloma cell refractory daratumumab . A good understanding variable may enable u improve quality duration daratumumab-induced response make daratumumab-based therapy effective near future .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Accepted clinical trial Daratumumab myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Daratumumab</keyword>
</DOC>